Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Serevelle
- Development stage
- Unknown
- Lead developer
- U.S. Nutraceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Topical
01
Overview
Serevelle (formerly known as USPlus DERM) is a proprietary, patented oral and topical botanical extract derived from saw palmetto (*Serenoa repens*) using Valensa International's ActiLipid4Hair technology. It is standardized to contain a concentrated mix of four bioactive free fatty acids. Serevelle acts primarily as an inhibitor of the 5-alpha reductase enzyme (types I and II), preventing the conversion of testosterone to dihydrotestosterone (DHT) to counter hair follicle miniaturization. Additionally, it exhibits a 5-alpha reductase-independent mechanism that prolongs the anagen (growth) phase of the hair cycle and supports the follicular stem cell niche. Serevelle is developed as a dietary supplement ingredient and nutricosmetic for thinning hair and hair loss (androgenetic alopecia) in both men and women.
- Brand names
- Serevelle
- Other names
- ActiLipid4HairActiLipid-4HairActiLipid 4HairSerenoa repens extractUSPlus DERMsaw palmetto extract
02
Targets
SRD5A1 (Steroid 5-alpha-reductase type 1)SRD5A2 (Steroid 5-alpha-reductase type II)
Beyond the preview
Go deeper on Serevelle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serevelle.